Current Pharmaceutical Biotechnology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Research Strategy for Short-Peptide Fusion Inhibitors Based on 6-HB Core Structure against HIV-1: A Review
Curr Pharm Biotechnol. 2024 Mar 28. doi: 10.2174/0113892010297943240325040448. Online ahead of print.ABSTRACTAcquired Immune Deficiency Syndrome (AIDS) is a devastating infectious disease caused by the Human Immunodeficiency Virus type 1 (HIV-1). Enfuvirtide(T20) is the first HIV-1 fusion inhibitor for marketing, which plays an important role in AIDS treatment. However, in the clinical application process, T20 has several drawbacks, such as a high level of development of drug resistance, a short half-life in vivo, and rapid renal clearance, which severely limits the clinical application. Therefore, the development of novel...
Source: Current Pharmaceutical Biotechnology - March 29, 2024 Category: Biotechnology Authors: Guodong Liang Yan Huang Yanbai Tang Lu Ga Caixia Huo Yuheng Ma Yan Zhao Heiya Na Zhao Meng Source Type: research

Targeted Drug Delivery to ACE2+ Cells Using Engineered Extracellular Vesicles: A Potential Therapeutic Approach for COVID-19
CONCLUSION: These findings indicate promising opportunities for engineered EVs as a novel nanomedicine carrier, offering valuable insights for therapeutic strategies against COVID-19 and other diseases.PMID:38551053 | DOI:10.2174/0113892010282251240324123038 (Source: Current Pharmaceutical Biotechnology)
Source: Current Pharmaceutical Biotechnology - March 29, 2024 Category: Biotechnology Authors: Yao Zhang Sheng-Jiao Song Jin He Zhuo-Hua Zhao Ke Zhang Yuan Zhang Xing Li Source Type: research

Exploring the Diagnostic and Prognostic Predictive Values of Ferroptosis- Related Markers in Lung Adenocarcinoma
CONCLUSION: Therapeutic targeting of these genes using specific drugs holds great promise for revolutionizing drug discovery and improving the overall survival of LUAD patients.PMID:38523537 | DOI:10.2174/0113892010293337240312051931 (Source: Current Pharmaceutical Biotechnology)
Source: Current Pharmaceutical Biotechnology - March 25, 2024 Category: Biotechnology Authors: Guoliang Mao Wuqin Xu Muhammad Jamil Wei Zhang Nanlin Jiao Yinhua Liu Source Type: research

Role of Phytoactive-based Nanoformulation for the Treatment of Arthritis
Curr Pharm Biotechnol. 2024 Mar 14. doi: 10.2174/0113892010276916240308082328. Online ahead of print.ABSTRACTJoints and arthritic conditions are among the most dangerous illnesses that humans have ever encountered and it is even more worrying that there is no recognized treatment for arthritis. The researchers looked for safer alternatives, such as herbal medicines, because the traditional treatments used to treat severe joint inflammatory issues have several negative side effects. A ligand-coated nanomedicine can bind to receptors that are overexpressed by cells in chronically inflammatory tissues, increasing its efficacy...
Source: Current Pharmaceutical Biotechnology - March 15, 2024 Category: Biotechnology Authors: Shivendra Kumar Kantrol Kumar Sahu Mohit Agrawal Kuldeep Singh Sunam Saha Source Type: research